Cyclooxygenase-2 blockade does not impair endothelial vasodilator function in healthy volunteers - Randomized evaluation of rofecoxib versus naproxen on endothelium-dependent vasodilatation

被引:59
作者
Verma, S
Raj, SR
Shewchuk, L
Mather, KJ
Anderson, TJ
机构
[1] Univ Toronto, Div Cardiac Surg, Toronto, ON, Canada
[2] Univ Calgary, Div Cardiol, Calgary, AB, Canada
关键词
endothelium-derived factors; patients; prostaglandins;
D O I
10.1161/hc4901.101350
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-From a cardiovascular standpoint. the safety of cyclooxygenase-2 (COX-2) blockers has been a topic of increasing concern. This concern stemmed from observations indicating that the COX-2 isoform is the major source of endothelium-derived prostacyclin and, hence, that selective blockade of this enzyme may impair endothelial health. To investigate this matter, we examined the effects of 7 days of treatment with rofecoxib versus naproxen on endothelial function in healthy Volunteers. Methods and Results-Thirty-five healthy volunteers were randomized to receive 7-day treatment with either rofecoxib (25 mg/d. n = 18) or naproxen (750 mg/d, n = 17). Vascular response measurements were conducted using forearm strain-gauge plethysmography. Changes in forearm blood flow in response to the endothelium-dependent vasodilator acetylcholine (3, 10, and 30 mug/min) and the endothelium-independent vasodilator sodium nitroprusside (1 and 10 mug/min) were assessed before and after treatment. Acetylcholine evoked a dose-dependent increase in forearm blood flow in all groups. Importantly, treatment resulted in no change in acetylcholine-mediated increases in forearm blood flow in either group (naproxen, P=0.27 rofecoxib, P=0.58). Similarly, there was no change in forearm blood flow in response to sodium nitroprusside (naproxen, P=0.55: rofecoxib, P=0.63). Conclusions-We herein describe, for the first time, the effects of COX-2-selective inhibition on endothelium-dependent vasodilatation in healthy adults. COX-2 blockade. when used at the doses employed therapeutically (which are known to inhibit vascular prostacyclin production) did not result in significant changes in endothelial vasodilator responses in healthy volunteers. The effects of COX-2 inhibitors on vasodilator responses in patients with coronary artery disease remain to be determined.
引用
收藏
页码:2879 / 2882
页数:4
相关论文
共 14 条
[1]   Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages [J].
Baker, CSR ;
Hall, RJC ;
Evans, TJ ;
Pomerance, A ;
Maclouf, J ;
Creminon, C ;
Yacoub, MH ;
Polak, JM .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (03) :646-655
[2]  
Belton O, 2000, CIRCULATION, V102, P840
[3]  
Catella-Lawson F, 1999, J PHARMACOL EXP THER, V289, P735
[4]   Effect of atherosclerosis on endothelium-dependent inhibition of platelet activation in humans [J].
Diodati, JG ;
Dakak, N ;
Gilligan, DM ;
Quyyumi, AA .
CIRCULATION, 1998, 98 (01) :17-24
[5]   Relative contribution of vasodilator prostanoids and NO to metabolic vasodilation in the human forearm [J].
Duffy, SJ ;
New, G ;
Tran, BT ;
Harper, RW ;
Meredith, IT .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1999, 276 (02) :H663-H670
[6]   Contribution of vasodilator prostanoids and nitric oxide to resting flow, metabolic vasodilation, and flow-mediated dilation in human coronary circulation [J].
Duffy, SJ ;
Castle, SF ;
Harper, RW ;
Meredith, IT .
CIRCULATION, 1999, 100 (19) :1951-1957
[7]  
DUFFY SJ, 1998, AM J PHYSIOL-HEART C, V274, pH1174
[8]   Drug therapy: The coxibs, selective inhibitors of cyclooxygenase-2. [J].
FitzGerald, GA ;
Patrono, C .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (06) :433-442
[9]   Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease [J].
Lipsky, PE ;
Brooks, P ;
Crofford, LJ ;
DuBois, R ;
Graham, D ;
Simon, LS ;
van de Putte, LBA ;
Abramson, SB .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (07) :913-920
[10]   Improved endothelial function with metformin in type 2 diabetes mellitus [J].
Mather, KJ ;
Verma, S ;
Anderson, TJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (05) :1344-1350